 
															 
																												At ESMO 2025, new data marked a major advance in breast cancer treatment. ADCs like trastuzumab deruxtecan and datopotamab deruxtecan significantly improved survival and reduced relapse...
 
															 
																												The GEICAM Breast Cancer Research Group reaffirms its leadership in Spanish oncology, according to SEOM’s 2024 report. With 108 clinical trials, 172 total studies, and 68,000...
 
															 
																												Technological advances in genomics, AI, and immunology are transforming breast cancer research, enabling personalized treatments and improved understanding of tumor biology. Key focuses include hereditary genetics,...